H.C. Wainwright reiterates Buy rating on Altimmune stock ahead of key 4Q25 catalysts
PositiveFinancial Markets

H.C. Wainwright has reaffirmed its Buy rating on Altimmune stock, highlighting the company's promising potential ahead of significant catalysts expected in the fourth quarter of 2025. This endorsement is crucial as it reflects confidence in Altimmune's growth prospects and could attract more investors, especially as the company approaches key developments that may impact its market performance.
— Curated by the World Pulse Now AI Editorial System